Thank you for the opportunity to ask the authors a question.
My question concerns the very poor rates of recovery in the tPA-treated cohort (median NIHSS 18), with only 6% achieving mRS 0-1 and 19% mRS 0-2. Contrast these outcomes with IMS-III in which the tPA-treated cohort (median NIHSS 16) achieved mRS 0-1 in 22% – including even the NIHSS ≥20 subgroup of IMS-III achieved mRS 0-1 in 11%. In fact, even the endovascular cohort of IMS-III with NIHSS ≥20 achieved mRS 0-1 in 15%, higher than the 12% observed in this cohort with median NIHSS 17. Obviously, there are pitfalls comparing enrollment populations and NIHSS is not the entire story, but I'm concerned the tPA cohort is a bit of a Straw Man comparator considering how unexpectedly unwell their outcomes were. I would hate to see the prospective evaluation of endovascular treatment stopped based solely on these data.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.